Hydralazine induced antinuclear cytoplasmic antibody vasculitis-patients with the pulmonary–renal syndrome, treatment and outcomes.
| Author with reference | Number of patients | Positive MPO antibodies | Pulmonary and renal involvement | Treatment | Outcome |
| Almroth et al20 | 17 | 12 of 14 tested | 4 | S 4/4 Cy 2/4 Az 1/4, P 1/4 | Three out of four died |
| Short and Lockwood23 | 10 | 10 | 2 | S 2/2 Cy 1/2 | Not reported |
| Choi et al7 | 10 | 10 | 5 | S 5/5 Cy 5/5 | One out of four died |
| Yokogawa and Vivino8 | 2 | 2 | 1 | S 1/1 Cy 1/1 | Died |
| Kalra et al24 | 1 | 1 | 1 | S 1/1 Cy 1/1 | Died |
| Babar et al19 | 2 | 1 | 1 | S1/1 Cy 1/1 | Died |
| Marina et al17 | 1 | 1 | 1 | S 1/1 Cy 1/1 | Died |
| Agarwal et al25 | 1 | 1 | 1 | S 1/1 Cy 1/1 | Survived |
| Namas et al26 | 1 | 1 | 1 | S 1/1 Cy 1/1 P 1/1 | Survived |
| Rasla et al27 | 1 | 1 | 1 | S1/1 Cy 1/1 P 1/1 | Survived |
| Kumar et al9 | 12 | 12 of 12 | 6 | S 5/6 Cy 5/6 MM 3/6 | Five out of six survived. |
Az, azathioprine; Cy, cyclophosphamide; MM, mycophenolate mofetil; P, plasmapheresis; S, steroids.